Literature DB >> 28919012

BRAFV600E and BRAF-inactivating mutations in NSCLC.

Rafael Rosell1, Niki Karachaliou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28919012     DOI： 10.1016/S1470-2045(17)30678-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.

Authors:  Amir Noeparast; Philippe Giron; Alfiah Noor; Rajendra Bahadur Shahi; Sylvia De Brakeleer; Carolien Eggermont; Hugo Vandenplas; Bram Boeckx; Diether Lambrechts; Jacques De Grève; Erik Teugels
Journal:  Oncogene       Date:  2019-07-08       Impact factor: 9.867

Review 2.  Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments.

Authors:  Kazuhiro Sase; Yasuhito Fujisaka; Masaaki Shoji; Mikio Mukai
Journal:  Curr Treat Options Oncol       Date:  2021-06-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.